Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 19;21(1):35.
doi: 10.1186/s12014-024-09483-8.

Correlation between small-cell lung cancer serum protein/peptides determined by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemotherapy efficacy

Zhihua Li #  1 , Junnan Chen #  1 , Bin Xu  2 , Wei Zhao  1 , Haoran Zha  1 , Yalin Han  1 , Wennan Shen  1 , Yuemei Dong  1 , Nan Zhao  1 , Manze Zhang  1 , Kun He  2 , Zhaoxia Li  3 , Xiaoqing Liu  4
Affiliations

Correlation between small-cell lung cancer serum protein/peptides determined by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemotherapy efficacy

Zhihua Li et al. Clin Proteomics. .

Abstract

Background: Currently, no effective measures are available to predict the curative efficacy of small-cell lung cancer (SCLC) chemotherapy. We expect to develop a method for effectively predicting the SCLC chemotherapy efficacy and prognosis in clinical practice in order to offer more pertinent therapeutic protocols for individual patients.

Methods: We adopted matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) and ClinPro Tools system to detect serum samples from 154 SCLC patients with different curative efficacy of standard chemotherapy and analyze the different peptides/proteins of SCLC patients to discover predictive tumor markers related to chemotherapy efficacy. Ten peptide/protein peaks were significantly different in the two groups.

Results: A genetic algorithm model consisting of four peptides/proteins was developed from the training group to separate patients with different chemotherapy efficacies. Among them, three peptides/proteins (m/z 3323.35, 6649.03 and 6451.08) showed high expression in the disease progression group, whereas the peptide/protein at m/z 4283.18 was highly expressed in the disease response group. The classifier exhibited an accuracy of 91.4% (53/58) in the validation group. The survival analysis showed that the median progression-free survival (PFS) of 30 SCLC patients in disease response group was 9.0 months; in 28 cases in disease progression group, the median PFS was 3.0 months, a statistically significant difference (χ2 = 46.98, P < 0.001). The median overall survival (OS) of the two groups was 13.0 months and 7.0 months, a statistically significant difference (χ2 = 40.64, P < 0.001).

Conclusions: These peptides/proteins may be used as potential biological markers for prediction of the curative efficacy and prognosis for SCLC patients treated with standard regimen chemotherapy.

Keywords: Chemotherapy; Matrix assisted laser desorption ionization-time of flight-mass spectrometry; Prediction of efficacy; Proteomics; Small-cell lung cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
The average spectra of the training set displayed in ClinPro tools. (A) Average spectra for disease response group I in the training group. (B) Average spectra for disease progression group I in the training group
Fig. 2
Fig. 2
ClinPro Tools image of the average intensity, in arbitrary units, of four peptides that represent the classifier in disease response group I and disease progression group I. (Red curve: Disease response group I; green curve: Disease progression group I)
Fig. 3
Fig. 3
Survival analysis of 58 patients in the validation group. (A) 29 patients were labeled as “Disease response group II” had obviously inferior PFS (P < 0.001) when compared to 29 patients were labeled as “Disease progression group II”. (B) 29 patients were labeled as “Disease response group II” had obviously inferior OS (P < 0.001) when compared to 29 patients were labeled as “Disease progression group II”
See this image and copyright information in PMC

References

    1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. Cancer J Clin. 2014;64(1):9–29. doi: 10.3322/caac.21208. - DOI - PubMed
    1. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367–80. doi: 10.1056/NEJMra0802714. - DOI - PMC - PubMed
    1. Lehtio J, De Petris L. Lung cancer proteomics, clinical and technological considerations. J Proteom. 2010;73(10):1851–63. doi: 10.1016/j.jprot.2010.05.015. - DOI - PubMed
    1. Cheng S, Evans WK, Stys-Norman D, Shepherd FA, Lung Cancer Disease Site Group of Cancer Care Ontario’s program in evidence-based C. Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2007;2(4):348–54. doi: 10.1097/01.JTO.0000263720.15062.51. - DOI - PubMed
    1. Hurwitz JL, McCoy F, Scullin P, Fennell DA. New advances in the second-line treatment of small cell lung cancer. Oncologist. 2009;14(10):986–94. doi: 10.1634/theoncologist.2009-0026. - DOI - PubMed

LinkOut - more resources